Cargando…

Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial

Background: Presumed benign ovarian tumours (PBOT) are defined by the International Ovarian Tumour Analysis (IOTA) group, without suspected sonographic criteria of cancer, without ascites or metastasis. The aim is to evaluate the efficacy of human epididymis protein 4 (HE4), cancer antigen 125 (CA12...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dochez, Vincent, Randet, Mélanie, Renaudeau, Céline, Dimet, Jérôme, Le Thuaut, Aurélie, Winer, Norbert, Thubert, Thibault, Vaucel, Edouard, Caillon, Hélène, Ducarme, Guillaume
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912210/ https://www.ncbi.nlm.nih.gov/pubmed/31699959 http://dx.doi.org/10.3390/jcm8111784

Ejemplares similares

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
por: Dochez, Vincent, et al.
Publicado: (2019)

A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses
por: Anton, Cristina, et al.
Publicado: (2012)

HE4 in the Diagnostic Approach of Endometrial Cancer in Patients with Postmenopausal Bleeding, the METRODEC Protocol: Protocol for a Multicenter Prospective Study
por: Degez, Manon, et al.
Publicado: (2021)

Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women
por: Cho, Hye Yon, et al.
Publicado: (2015)

Morphological parameters of ovarian masses and accuracy of the risk of malignancy index in diagnosing ovarian malignancy
por: Adilgereyeva, Akmaral S., et al.
Publicado: (2022)

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
por: Van Gorp, T, et al.
Publicado: (2011)

Multivariate Index Assay Is Superior to CA125 and HE4 Testing in Detection of Ovarian Malignancy in African-American Women
por: Dunton, Charles, et al.
Publicado: (2019)

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses
por: Pitta, Denise da Rocha, et al.
Publicado: (2013)

CA-125 and risk of malignancy index for screening for malignancy in fertile aged females with ovarian cyst, which is more cost effectiveness?
por: Wiwanitkit, Viroj
Publicado: (2013)

Accuracy of the risk of malignancy index-I in diagnosing ovarian malignancy in menopausal women
por: Radwan, Ahmed M., et al.
Publicado: (2023)

Copenhagen index (CPH-I) is more favorable than CA125, HE4, and risk of ovarian malignancy algorithm (ROMA): Nomogram prediction models with clinical-ultrasonographic feature for diagnosing ovarian neoplasms
por: Song, Zixuan, et al.
Publicado: (2023)

The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4
por: Han, Kyung Hee, et al.
Publicado: (2019)

The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer
por: WEI, SU, et al.
Publicado: (2016)

Preoperative Evaluation of Risk of Ovarian Malignancy Algorithm Index in Prediction of Malignancy of Adnexal Masses
por: Farzaneh, Farah, et al.
Publicado: (2014)

Diagnostic value of risk of malignancy index in the clinical evaluation of ovarian mass
por: Huwidi, Ali, et al.
Publicado: (2022)

Is Risk Malignancy Index a Useful Tool for Predicting Malignant Ovarian Masses in Developing Countries?
por: Aziz, Aliya B., et al.
Publicado: (2015)

Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125
por: Chudecka-Głaz, Anita, et al.
Publicado: (2016)

The value of a vaginal sample for detecting PAMG-1 (Partosure®) in women with a threatened preterm delivery (the MAPOSURE Study): protocol for a multicenter prospective study
por: Marie, Emilie, et al.
Publicado: (2020)

Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria
por: Shittu, Khadijah Adebisi, et al.
Publicado: (2023)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

Diagnostic value of CA125, HE4, and systemic immune-inflammation index in the preoperative investigation of ovarian masses
por: Song, Liyun, et al.
Publicado: (2023)

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
por: Huhtinen, K, et al.
Publicado: (2009)

Adnexal mass with extremely high levels of CA-125 and CA19-9 but normal Human Epididymis Protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA): Endometriosis or ovarian malignancy? A case report
por: Khodaverdi, Sepideh, et al.
Publicado: (2018)

The performance of the risk of ovarian malignancy algorithm
por: Langmár, Z, et al.
Publicado: (2011)

Comparisons of Effectiveness in Differentiating Benign from Malignant Ovarian Masses between Conventional and Modified Risk of Malignancy Index (RMI)
por: Tantipalakorn, Charuwan, et al.
Publicado: (2023)

Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors
por: Zhang, Shuang, et al.
Publicado: (2019)

Diagnostic accuracy of the Copenhagen Index in ovarian malignancy: A meta-analysis
por: Liu, Huiling, et al.
Publicado: (2023)

The Comparison of Three Predictive Indexes to Discriminate Malignant Ovarian Tumors from Benign Ovarian Endometrioma: The Characteristics and Efficacy
por: Yamanaka, Shoichiro, et al.
Publicado: (2022)

Analysis of falsely elevated risk of ovarian malignancy algorithm in women with ovarian endometrioma
por: Shin, Jae Jun, et al.
Publicado: (2016)

Reply: The performance of the risk of ovarian malignancy algorithm
por: Van Gorp, T, et al.
Publicado: (2011)

Decidualized Ovarian Mass Mimicking Malignancy
por: Wong, Lufee, et al.
Publicado: (2015)

Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?
por: Abdalla, Nabil, et al.
Publicado: (2018)

Comparison of four malignancy risk indices in the detection of malignant ovarian masses
por: Aktürk, Erhan, et al.
Publicado: (2011)

Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer: A meta-analysis
por: Li, Fake, et al.
Publicado: (2012)

A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass
por: Dora, Santosh Kumar, et al.
Publicado: (2017)

Early identification of recurrence in ovarian cancer: a comparison between the ovarian cancer metastasis index and CA-125 levels
por: Wang, Fei, et al.
Publicado: (2018)

Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative
por: Dunton, Charles J., et al.
Publicado: (2021)

Comparison of glutaminase and cancer antigen 125 for distinguishing benign and malignant ovarian tumors
por: Winarno, Gatot Nyarumenteng Adhipurnawan, et al.
Publicado: (2023)

Ropivacaine 75 mg versus placebo in perineal infiltration for analgesic efficacy at mid- and long-term for episiotomy repair in postpartum women – the ROPISIO study: a two-center, randomized, double-blind, placebo-controlled trials
por: Cardaillac, Claire, et al.
Publicado: (2020)

Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass
por: Partheen, Karolina, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ni29nqun85f03gqufdc378ct3g